Hemato-Oncology Latin America Observational Registry in CLL, Multiple Myeloma, Non-Hodgkin Lymphoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,443
- 主要终点
- Number of Participants with Previous Comorbidities
研究概览
简要总结
The primary purpose of the study is to quantify participants' demographic parameters, country standard therapies, treatment patterns and outcomes among participants with chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) in oncology concentration hospitals in Latin America.
详细描述
This is a retrospective (take a look back at events that already have taken place), non-interventional, multicenter (when more than one hospital or medical school team work on a medical research study) study to review medical records of adult participants with a diagnosis of CLL, MM or NHL anytime since 01 January 2006. Only data available from clinical practice will be collected. All eligible participants at participating centers will be included regardless of participant's demographics, prior or current treatments for disease, or clinical outcome. The period of observation will span from 01 January 2006 through present, but all eligible participants must be followed for a minimum of 1 year, unless the participant died within that first year. Participant demographic parameters, standard therapies, treatment patterns and outcomes will be primarily quantified.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or non-Hodgkin lymphoma (NHL) anytime since January 1, 2006
- •At least one year of data following first observed diagnosis except in the case of the participant death within one year following first observed diagnosis
- •Participant must sign a participation agreement/informed consent form (ICF)
排除标准
- •Having one and only one consult in the center
结局指标
主要结局
Number of Participants with Previous Comorbidities
时间窗: 1 year
Comorbidities included: heart, diabetes, hypertension, renal, infections, other neoplasia, neurologic, rheumatologic, HIV, thrombosis, bone and other.
Number of Participants as per treatment therapy received
时间窗: 1 year
Cancer treatment (Chronic Lymphocytic Leukemia \[CLL\], Multiple Myeloma \[MM\] and non-Hodgkin lymphoma \[NHL\]) for all participants is summarized by the number of participants who had any type of surgery or radiotherapy (external radiation or brachytherapy) or other drug treatments.
Overall survival
时间窗: 1 year
Overall Survival (OS) was defined as the time from date of starting treatment to death due to any cause.
Number of Participants with Response to Treatment
时间窗: 1 year
Number of participants who responded to treatment is presented. Treatment response will be assessed based on complete response or partial response.
次要结局
- Incidence Percentage of Participants with Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and non-Hodgkin lymphoma (NHL)(1 year)
- Prevalence Percentage of Participants with CLL, MM and NHL(1 year)